Long- and Short-Term Cost-Effectiveness of Once-Weekly Semaglutide versus Dulaglutide for the Treatment of Type 2 Diabetes in China: A Hypothetical Modeling Exercise.

Hu Y, Zou H, Shen Y, Ni Q, Li Y, Zhang H, Chen X, Ung COL, Hu H, Mu Y

Diabetes therapy : research, treatment and education of diabetes and related disorders19 Mar 2025Cited by 3 (Europe PMC)

PMID40106226PMCIDPMC12006588DOI10.1007/s13300-025-01716-9PepBankPUB-40106226

Read at source PubMedAsk about this study

Jump to 14 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study14

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone14

In this study, the peptide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking the peptide.

01Computer modelNot a test of Semaglutide aloneIn silicoOther
In a Chinese T2D model, semaglutide 0.5 mg increased QALYs by 0.08 versus dulaglutide 1.5 mg.
In plain wordsA diabetes computer model predicted 0.08 more quality-adjusted life years with semaglutide 0.5 mg than dulaglutide 1.5 mg.
Peptide
Semaglutide
Outcome
IncreaseQALYs, semaglutide 0.5 mg
Study
n: not reported in source
IHE-DCM
Comparator
Dulaglutide 1.5 mg
Analysis
Primary
Outcome group
Cost-effectiveness · Whole body
Source sentences
Summary
Compared with dulaglutide 1.5 mg, once-weekly semaglutide 0.5 mg demonstrated an improvement of 0.08 QALYs and a reduction in total direct medical costs of 5476 Chinese yuan (CNY); Once-weekly semaglutide 1.0 mg showed an increase of 0.19 QALYs, and a decrease in total direct medical costs of 6711 CNY.
3 context sentences(design, population, supporting numbers)
Summary · context
The long-term cost-effectiveness analysis used quality-adjusted life years (QALYs) as the primary health outcome.
Summary · context
This study aimed to evaluate the long- and short-term cost-effectiveness of once-weekly semaglutide versus dulaglutide for treating patients with type 2 diabetes uncontrolled with metformin after the renewal of China's national reimbursement drug list.
Summary · context
This analysis was conducted using the Institute of Health Economics Diabetes Cohort Model (IHE-DCM) to evaluate the long-term health and economic outcomes of semaglutide 0.5 mg, 1.0 mg, and dulaglutide 1.5 mg.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-4010622601
02Computer modelNot a test of Semaglutide aloneIn silicoOther
In a Chinese T2D model, semaglutide 1.0 mg increased QALYs by 0.19 versus dulaglutide 1.5 mg.
In plain wordsA diabetes computer model predicted 0.19 more quality-adjusted life years with semaglutide 1.0 mg than dulaglutide 1.5 mg.
Peptide
Semaglutide
Outcome
IncreaseQALYs, semaglutide 1.0 mg
Study
n: not reported in source
IHE-DCM
Comparator
Dulaglutide 1.5 mg
Analysis
Primary
Outcome group
Cost-effectiveness · Whole body
Source sentences
Summary
Compared with dulaglutide 1.5 mg, once-weekly semaglutide 0.5 mg demonstrated an improvement of 0.08 QALYs and a reduction in total direct medical costs of 5476 Chinese yuan (CNY); Once-weekly semaglutide 1.0 mg showed an increase of 0.19 QALYs, and a decrease in total direct medical costs of 6711 CNY.
3 context sentences(design, population, supporting numbers)
Summary · context
The long-term cost-effectiveness analysis used quality-adjusted life years (QALYs) as the primary health outcome.
Summary · context
This study aimed to evaluate the long- and short-term cost-effectiveness of once-weekly semaglutide versus dulaglutide for treating patients with type 2 diabetes uncontrolled with metformin after the renewal of China's national reimbursement drug list.
Summary · context
This analysis was conducted using the Institute of Health Economics Diabetes Cohort Model (IHE-DCM) to evaluate the long-term health and economic outcomes of semaglutide 0.5 mg, 1.0 mg, and dulaglutide 1.5 mg.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-4010622603
03Computer modelNot a test of Dulaglutide (Trulicity) aloneIn silicoOther
In a Chinese T2D model, dulaglutide 1.5 mg yielded fewer QALYs than semaglutide 0.5 mg.
In plain wordsA diabetes computer model predicted fewer quality-adjusted life years with dulaglutide 1.5 mg than semaglutide 0.5 mg.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseQALYs versus semaglutide 0.5 mg
Study
n: not reported in source
IHE-DCM
Comparator
Semaglutide 0.5 mg
Analysis
Primary
Outcome group
Cost-effectiveness · Whole body
Source sentences
Summary
Compared with dulaglutide 1.5 mg, once-weekly semaglutide 0.5 mg demonstrated an improvement of 0.08 QALYs and a reduction in total direct medical costs of 5476 Chinese yuan (CNY); Once-weekly semaglutide 1.0 mg showed an increase of 0.19 QALYs, and a decrease in total direct medical costs of 6711 CNY.
3 context sentences(design, population, supporting numbers)
Summary · context
The long-term cost-effectiveness analysis used quality-adjusted life years (QALYs) as the primary health outcome.
Summary · context
This study aimed to evaluate the long- and short-term cost-effectiveness of once-weekly semaglutide versus dulaglutide for treating patients with type 2 diabetes uncontrolled with metformin after the renewal of China's national reimbursement drug list.
Summary · context
This analysis was conducted using the Institute of Health Economics Diabetes Cohort Model (IHE-DCM) to evaluate the long-term health and economic outcomes of semaglutide 0.5 mg, 1.0 mg, and dulaglutide 1.5 mg.
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Report a problemFND-4010622608
04Computer modelNot a test of Dulaglutide (Trulicity) aloneIn silicoOther
In a Chinese T2D model, dulaglutide 1.5 mg yielded fewer QALYs than semaglutide 1.0 mg.
In plain wordsA diabetes computer model predicted fewer quality-adjusted life years with dulaglutide 1.5 mg than semaglutide 1.0 mg.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseQALYs versus semaglutide 1.0 mg
Study
n: not reported in source
IHE-DCM
Comparator
Semaglutide 1.0 mg
Analysis
Primary
Outcome group
Cost-effectiveness · Whole body
Source sentences
Summary
Compared with dulaglutide 1.5 mg, once-weekly semaglutide 0.5 mg demonstrated an improvement of 0.08 QALYs and a reduction in total direct medical costs of 5476 Chinese yuan (CNY); Once-weekly semaglutide 1.0 mg showed an increase of 0.19 QALYs, and a decrease in total direct medical costs of 6711 CNY.
3 context sentences(design, population, supporting numbers)
Summary · context
The long-term cost-effectiveness analysis used quality-adjusted life years (QALYs) as the primary health outcome.
Summary · context
This study aimed to evaluate the long- and short-term cost-effectiveness of once-weekly semaglutide versus dulaglutide for treating patients with type 2 diabetes uncontrolled with metformin after the renewal of China's national reimbursement drug list.
Summary · context
This analysis was conducted using the Institute of Health Economics Diabetes Cohort Model (IHE-DCM) to evaluate the long-term health and economic outcomes of semaglutide 0.5 mg, 1.0 mg, and dulaglutide 1.5 mg.
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Report a problemFND-4010622609
05Computer modelNot a test of Semaglutide aloneIn silicoOther
In a Chinese T2D model, semaglutide 0.5 mg reduced direct medical costs by 5476 CNY versus dulaglutide 1.5 mg.
In plain wordsA diabetes computer model predicted 5476 CNY lower medical costs with semaglutide 0.5 mg than dulaglutide 1.5 mg.
Peptide
Semaglutide
Outcome
DecreaseDirect medical costs, semaglutide 0.5 mg
Study
n: not reported in source
IHE-DCM
Comparator
Dulaglutide 1.5 mg
Outcome group
Cost-effectiveness · Whole body
Source sentences
Summary
Compared with dulaglutide 1.5 mg, once-weekly semaglutide 0.5 mg demonstrated an improvement of 0.08 QALYs and a reduction in total direct medical costs of 5476 Chinese yuan (CNY); Once-weekly semaglutide 1.0 mg showed an increase of 0.19 QALYs, and a decrease in total direct medical costs of 6711 CNY.
2 context sentences(design, population, supporting numbers)
Summary · context
This study aimed to evaluate the long- and short-term cost-effectiveness of once-weekly semaglutide versus dulaglutide for treating patients with type 2 diabetes uncontrolled with metformin after the renewal of China's national reimbursement drug list.
Summary · context
This analysis was conducted using the Institute of Health Economics Diabetes Cohort Model (IHE-DCM) to evaluate the long-term health and economic outcomes of semaglutide 0.5 mg, 1.0 mg, and dulaglutide 1.5 mg.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-4010622602
06Computer modelNot a test of Semaglutide aloneIn silicoOther
In a Chinese T2D model, semaglutide 1.0 mg reduced direct medical costs by 6711 CNY versus dulaglutide 1.5 mg.
In plain wordsA diabetes computer model predicted 6711 CNY lower medical costs with semaglutide 1.0 mg than dulaglutide 1.5 mg.
Peptide
Semaglutide
Outcome
DecreaseDirect medical costs, semaglutide 1.0 mg
Study
n: not reported in source
IHE-DCM
Comparator
Dulaglutide 1.5 mg
Outcome group
Cost-effectiveness · Whole body
Source sentences
Summary
Compared with dulaglutide 1.5 mg, once-weekly semaglutide 0.5 mg demonstrated an improvement of 0.08 QALYs and a reduction in total direct medical costs of 5476 Chinese yuan (CNY); Once-weekly semaglutide 1.0 mg showed an increase of 0.19 QALYs, and a decrease in total direct medical costs of 6711 CNY.
2 context sentences(design, population, supporting numbers)
Summary · context
This study aimed to evaluate the long- and short-term cost-effectiveness of once-weekly semaglutide versus dulaglutide for treating patients with type 2 diabetes uncontrolled with metformin after the renewal of China's national reimbursement drug list.
Summary · context
This analysis was conducted using the Institute of Health Economics Diabetes Cohort Model (IHE-DCM) to evaluate the long-term health and economic outcomes of semaglutide 0.5 mg, 1.0 mg, and dulaglutide 1.5 mg.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-4010622604
07Computer modelNot a test of Semaglutide aloneIn silicoOther
In a Chinese T2D model, semaglutide 0.5 mg had lower treatment costs for all targets than dulaglutide 1.5 mg.
In plain wordsA diabetes computer model predicted lower costs for all treatment targets with semaglutide 0.5 mg than dulaglutide 1.5 mg.
Peptide
Semaglutide
Outcome
DecreaseCost of control, semaglutide 0.5 mg
Study
n: not reported in source
IHE-DCM
Comparator
Dulaglutide 1.5 mg
Outcome group
Cost-effectiveness · Whole body
Source sentences
Summary
In the short-term cost-of-control study, once-weekly semaglutide 0.5 mg demonstrated lower treatment costs for all targets: the costs of control for dulaglutide 1.5 mg were 1.2-2.1 times as much as that of semaglutide 0.5 mg once weekly.
2 context sentences(design, population, supporting numbers)
Summary · context
This study aimed to evaluate the long- and short-term cost-effectiveness of once-weekly semaglutide versus dulaglutide for treating patients with type 2 diabetes uncontrolled with metformin after the renewal of China's national reimbursement drug list.
Summary · context
This analysis was conducted using the Institute of Health Economics Diabetes Cohort Model (IHE-DCM) to evaluate the long-term health and economic outcomes of semaglutide 0.5 mg, 1.0 mg, and dulaglutide 1.5 mg.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-4010622605
08Computer modelNot a test of Semaglutide aloneIn silicoOther
In a Chinese T2D model, semaglutide 1.0 mg had similar good-glycemic-control costs to dulaglutide 1.5 mg.
In plain wordsA diabetes computer model predicted similar costs for good glucose control with semaglutide 1.0 mg and dulaglutide 1.5 mg.
Peptide
Semaglutide
Outcome
No significant changeCost of good glycemic control, semaglutide 1.0 mg
Study
n: not reported in source
IHE-DCM
Comparator
Dulaglutide 1.5 mg
Outcome group
Cost-effectiveness · Whole body
Source sentences
Summary
Semaglutide 1.0 mg achieved similar treatment costs for the good glycemic control goal (HbA_1c < 7%) to dulaglutide 1.5 mg.
2 context sentences(design, population, supporting numbers)
Summary · context
This study aimed to evaluate the long- and short-term cost-effectiveness of once-weekly semaglutide versus dulaglutide for treating patients with type 2 diabetes uncontrolled with metformin after the renewal of China's national reimbursement drug list.
Summary · context
This analysis was conducted using the Institute of Health Economics Diabetes Cohort Model (IHE-DCM) to evaluate the long-term health and economic outcomes of semaglutide 0.5 mg, 1.0 mg, and dulaglutide 1.5 mg.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-4010622606
09Computer modelNot a test of Semaglutide aloneIn silicoOther
In a Chinese T2D model, semaglutide 1.0 mg had lower costs for tight glycemic, weight management and composite weight-loss targets than dulaglutide 1.5 mg.
In plain wordsA computer model predicted lower costs for tight glucose, weight and composite targets with semaglutide 1.0 mg than dulaglutide 1.5 mg.
Peptide
Semaglutide
Outcome
DecreaseCost of tight glycemic, weight management and composite weight-loss targets
Study
n: not reported in source
IHE-DCM
Comparator
Dulaglutide 1.5 mg
Outcome group
Cost-effectiveness · Whole body
Source sentences
Summary
However, when looking at tight glycemic control, weight management targets, and composite targets relating to weight loss, once-weekly semaglutide 1.0 mg showed lower treatment costs compared to dulaglutide 1.5 mg to bring at least one patient to achieve these targets.
2 context sentences(design, population, supporting numbers)
Summary · context
This study aimed to evaluate the long- and short-term cost-effectiveness of once-weekly semaglutide versus dulaglutide for treating patients with type 2 diabetes uncontrolled with metformin after the renewal of China's national reimbursement drug list.
Summary · context
This analysis was conducted using the Institute of Health Economics Diabetes Cohort Model (IHE-DCM) to evaluate the long-term health and economic outcomes of semaglutide 0.5 mg, 1.0 mg, and dulaglutide 1.5 mg.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-4010622607
10Computer modelNot a test of Dulaglutide (Trulicity) aloneIn silicoOther
In a Chinese T2D model, dulaglutide 1.5 mg had higher direct medical costs than semaglutide 0.5 mg.
In plain wordsA diabetes computer model predicted higher medical costs with dulaglutide 1.5 mg than semaglutide 0.5 mg.
Peptide
Dulaglutide (Trulicity)
Outcome
IncreaseDirect costs versus semaglutide 0.5 mg
Study
n: not reported in source
IHE-DCM
Comparator
Semaglutide 0.5 mg
Outcome group
Cost-effectiveness · Whole body
Source sentences
Summary
Compared with dulaglutide 1.5 mg, once-weekly semaglutide 0.5 mg demonstrated an improvement of 0.08 QALYs and a reduction in total direct medical costs of 5476 Chinese yuan (CNY); Once-weekly semaglutide 1.0 mg showed an increase of 0.19 QALYs, and a decrease in total direct medical costs of 6711 CNY.
2 context sentences(design, population, supporting numbers)
Summary · context
This study aimed to evaluate the long- and short-term cost-effectiveness of once-weekly semaglutide versus dulaglutide for treating patients with type 2 diabetes uncontrolled with metformin after the renewal of China's national reimbursement drug list.
Summary · context
This analysis was conducted using the Institute of Health Economics Diabetes Cohort Model (IHE-DCM) to evaluate the long-term health and economic outcomes of semaglutide 0.5 mg, 1.0 mg, and dulaglutide 1.5 mg.
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Report a problemFND-4010622610
11Computer modelNot a test of Dulaglutide (Trulicity) aloneIn silicoOther
In a Chinese T2D model, dulaglutide 1.5 mg had higher direct medical costs than semaglutide 1.0 mg.
In plain wordsA diabetes computer model predicted higher medical costs with dulaglutide 1.5 mg than semaglutide 1.0 mg.
Peptide
Dulaglutide (Trulicity)
Outcome
IncreaseDirect costs versus semaglutide 1.0 mg
Study
n: not reported in source
IHE-DCM
Comparator
Semaglutide 1.0 mg
Outcome group
Cost-effectiveness · Whole body
Source sentences
Summary
Compared with dulaglutide 1.5 mg, once-weekly semaglutide 0.5 mg demonstrated an improvement of 0.08 QALYs and a reduction in total direct medical costs of 5476 Chinese yuan (CNY); Once-weekly semaglutide 1.0 mg showed an increase of 0.19 QALYs, and a decrease in total direct medical costs of 6711 CNY.
2 context sentences(design, population, supporting numbers)
Summary · context
This study aimed to evaluate the long- and short-term cost-effectiveness of once-weekly semaglutide versus dulaglutide for treating patients with type 2 diabetes uncontrolled with metformin after the renewal of China's national reimbursement drug list.
Summary · context
This analysis was conducted using the Institute of Health Economics Diabetes Cohort Model (IHE-DCM) to evaluate the long-term health and economic outcomes of semaglutide 0.5 mg, 1.0 mg, and dulaglutide 1.5 mg.
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Report a problemFND-4010622611
12Computer modelNot a test of Dulaglutide (Trulicity) aloneIn silicoOther
In a Chinese T2D model, dulaglutide 1.5 mg had higher treatment costs for all targets than semaglutide 0.5 mg.
In plain wordsA diabetes computer model predicted higher costs for all treatment targets with dulaglutide 1.5 mg than semaglutide 0.5 mg.
Peptide
Dulaglutide (Trulicity)
Outcome
IncreaseCost of control versus semaglutide 0.5 mg
Study
n: not reported in source
IHE-DCM
Comparator
Semaglutide 0.5 mg
Outcome group
Cost-effectiveness · Whole body
Source sentences
Summary
In the short-term cost-of-control study, once-weekly semaglutide 0.5 mg demonstrated lower treatment costs for all targets: the costs of control for dulaglutide 1.5 mg were 1.2-2.1 times as much as that of semaglutide 0.5 mg once weekly.
2 context sentences(design, population, supporting numbers)
Summary · context
This study aimed to evaluate the long- and short-term cost-effectiveness of once-weekly semaglutide versus dulaglutide for treating patients with type 2 diabetes uncontrolled with metformin after the renewal of China's national reimbursement drug list.
Summary · context
This analysis was conducted using the Institute of Health Economics Diabetes Cohort Model (IHE-DCM) to evaluate the long-term health and economic outcomes of semaglutide 0.5 mg, 1.0 mg, and dulaglutide 1.5 mg.
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Report a problemFND-4010622612
13Computer modelNot a test of Dulaglutide (Trulicity) aloneIn silicoOther
In a Chinese T2D model, dulaglutide 1.5 mg had similar good-glycemic-control costs to semaglutide 1.0 mg.
In plain wordsA diabetes computer model predicted similar costs for good glucose control with dulaglutide 1.5 mg and semaglutide 1.0 mg.
Peptide
Dulaglutide (Trulicity)
Outcome
Direction not reportedCost of good glycemic control
Study
n: not reported in source
IHE-DCM
Comparator
Semaglutide 1.0 mg
Outcome group
Cost-effectiveness · Whole body
Source sentences
Summary
Semaglutide 1.0 mg achieved similar treatment costs for the good glycemic control goal (HbA_1c < 7%) to dulaglutide 1.5 mg.
2 context sentences(design, population, supporting numbers)
Summary · context
This study aimed to evaluate the long- and short-term cost-effectiveness of once-weekly semaglutide versus dulaglutide for treating patients with type 2 diabetes uncontrolled with metformin after the renewal of China's national reimbursement drug list.
Summary · context
This analysis was conducted using the Institute of Health Economics Diabetes Cohort Model (IHE-DCM) to evaluate the long-term health and economic outcomes of semaglutide 0.5 mg, 1.0 mg, and dulaglutide 1.5 mg.
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Report a problemFND-4010622613
14Computer modelNot a test of Dulaglutide (Trulicity) aloneIn silicoOther
In a Chinese T2D model, dulaglutide 1.5 mg had higher costs for tight glycemic, weight management and composite weight-loss targets than semaglutide 1.0 mg.
In plain wordsA computer model predicted higher costs for tight glucose, weight and composite targets with dulaglutide 1.5 mg than semaglutide 1.0 mg.
Peptide
Dulaglutide (Trulicity)
Outcome
IncreaseCost of tight glycemic, weight management and composite weight-loss targets
Study
n: not reported in source
IHE-DCM
Comparator
Semaglutide 1.0 mg
Outcome group
Cost-effectiveness · Whole body
Source sentences
Summary
However, when looking at tight glycemic control, weight management targets, and composite targets relating to weight loss, once-weekly semaglutide 1.0 mg showed lower treatment costs compared to dulaglutide 1.5 mg to bring at least one patient to achieve these targets.
2 context sentences(design, population, supporting numbers)
Summary · context
This study aimed to evaluate the long- and short-term cost-effectiveness of once-weekly semaglutide versus dulaglutide for treating patients with type 2 diabetes uncontrolled with metformin after the renewal of China's national reimbursement drug list.
Summary · context
This analysis was conducted using the Institute of Health Economics Diabetes Cohort Model (IHE-DCM) to evaluate the long-term health and economic outcomes of semaglutide 0.5 mg, 1.0 mg, and dulaglutide 1.5 mg.
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Report a problemFND-4010622614

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 3Current
22 Oct 2026, 02:25 UTC
Study results updated
Version 2
21 Oct 2026, 18:59 UTC
Study data updated · source update from Europe PMC
Version 1
9 Oct 2026, 03:06 UTC
First added · source update from Europe PMC

Long- and Short-Term Cost-Effectiveness of Once-Weekly Semaglutide versus Dulaglutide for the Treatment of Type 2 Diabetes in China: A Hypothetical Modeling Exercise.

Summary

Results from this study14

Studies that did not test the peptide alone14

Version history

Subjects

Publication types

Keywords